Management of Acute Urethritis with Urethral Discharge
Epidemiology & Rationale
- In patients presenting with dysuria and urethral discharge after recent sexual contact, empiric coverage for Neisseria gonorrhoeae and Chlamydia trachomatis is mandatory because a large proportion of gonorrhea cases are co‑infected with chlamydia, often without symptoms. CDC recommends dual therapy. 1
Recommended Antimicrobial Regimen
- Gonorrhea coverage: ceftriaxone 125 – 250 mg intramuscularly as a single dose. CDC recommends this dose range. 1
- Chlamydia coverage (mandatory addition): either doxycycline 100 mg orally twice daily for 7 days or azithromycin 1 g orally as a single dose. Both options are endorsed by the CDC. 1
- Complete dual therapy (ceftriaxone + doxycycline or ceftriaxone + azithromycin) is required; using either agent alone leaves the infection partially untreated. 1
Patient Counseling & Partner Management
- Patients should abstain from sexual activity for 7 days after therapy initiation and until all symptoms have resolved. CDC guidance. 1
- Sexual activity should also be avoided until all recent partners have been treated. 1
- All sexual partners within the preceding 60 days must be evaluated and treated empirically for both gonorrhea and chlamydia. This is a CDC recommendation. 1
- Expedited partner therapy (providing prescriptions to partners without prior clinical evaluation) is advised when partner follow‑up is unlikely. 1
Treatment Pitfalls to Avoid
- Never prescribe gonorrhea therapy without concurrent chlamydia coverage because coinfection rates are high. 1
- Quinolones (e.g., ciprofloxacin, ofloxacin) should not be used for gonorrhea due to widespread antimicrobial resistance. 1
- Azithromycin alone is insufficient for empiric urethritis treatment; it does not reliably treat gonorrhea and promotes resistance. 1
- Ceftriaxone alone fails to eradicate chlamydia, risking persistent infection and complications. 1
Follow‑Up & Retesting
- No test‑of‑cure is required when the recommended dual regimen is used and the patient’s symptoms have resolved. 1
- Retesting (NAAT for gonorrhea and chlamydia) should be performed 3 months after treatment, irrespective of partner treatment status, because reinfection is common. 1
- If symptoms persist after therapy, clinicians should assess for treatment failure, reinfection, or infection with alternative pathogens such as Mycoplasma genitalium or Trichomonas vaginalis. This recommendation is supported by European Urology guidelines. 2
Empiric Treatment for Male STIs
Indications for Empiric Treatment
- The Centers for Disease Control and Prevention (CDC) recommends empiric treatment for males with urethritis when mucopurulent or purulent urethral discharge is present, Gram stain shows ≥5 WBCs per oil immersion field, first-void urine microscopy demonstrates ≥10 WBCs per high-power field, or positive leukocyte esterase test on first-void urine 3
- Empiric treatment is still recommended for men at high risk who are unlikely to return for follow-up evaluation, recognizing the reality of clinical practice where loss to follow-up is common and untreated infections lead to ongoing transmission and complications 3
Rationale for Dual Therapy
- Dual therapy is essential because chlamydia coinfection occurs in a substantial proportion of gonorrhea cases, and testing delays mean treatment cannot wait for results before initiating therapy 3
- Untreated chlamydia leads to complications including epididymitis, urethral stricture, and facilitates HIV transmission 3
- Reinfection from untreated partners is the primary cause of treatment failure, highlighting the importance of treating all sexual partners within the preceding 60 days empirically for both gonorrhea and chlamydia 4
Special Considerations
- If persistent or recurrent urethritis occurs after standard treatment, test for M. genitalium using NAAT with macrolide resistance testing when available, and consider alternative treatments such as azithromycin or moxifloxacin 5
- Azithromycin is preferred over doxycycline for M. genitalium, with an 85-95% cure rate compared to 30-40% for doxycycline 5
Critical Management Steps
- Instruct patients to abstain from sexual intercourse for 7 days after initiating therapy and until symptoms resolve, and to abstain until all sex partners are treated to prevent reinfection 3
- All sexual partners within the preceding 60 days must be evaluated and treated empirically for both gonorrhea and chlamydia, regardless of symptoms or test results 4
Additional Testing
- All patients diagnosed with an STI should receive syphilis serology and HIV testing with counseling, addressing the reality that STIs cluster and patients with one infection are at higher risk for others 3
Common Pitfalls to Avoid
- Do not treat based on symptoms alone without objective evidence of urethritis, as this leads to overtreatment and antimicrobial resistance 6
- Do not use quinolones for gonorrhea, as resistance is now widespread and these are no longer recommended 7
- Do not delay treatment waiting for test results, as empiric therapy should be initiated immediately when clinical criteria are met 3